These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1534176)

  • 1. Does ondansetron attenuate amphetamine-induced behaviour in human volunteers?
    Silverstone PH; Johnson B; Cowen PJ
    Psychopharmacology (Berl); 1992; 107(1):140-1. PubMed ID: 1534176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers.
    Silverstone PH; Oldman D; Johnson B; Cowen PJ
    Int Clin Psychopharmacol; 1992; 7(1):37-43. PubMed ID: 1385603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers.
    Grady TA; Broocks A; Canter SK; Pigott TA; Dubbert B; Hill JL; Murphy DL
    Psychiatry Res; 1996 Aug; 64(1):1-10. PubMed ID: 8888359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT3 receptor antagonist ondansetron does not alter effects of amphetamine on DA metabolism.
    Koulu M; Lappalainen J; Hietala J; Sjöholm B; Virtanen R
    Neuroreport; 1990 Oct; 1(2):126-8. PubMed ID: 2151795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 5-HT3 receptor antagonists on the discriminative stimulus effects of amphetamine.
    Moser PC
    Eur J Pharmacol; 1992 Mar; 212(2-3):271-4. PubMed ID: 1534768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.
    Warburton EC; Joseph MH; Feldon J; Weiner I; Gray JA
    Psychopharmacology (Berl); 1994 May; 114(4):657-64. PubMed ID: 7855229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist.
    Gore S; Gilmore IT; Haigh CG; Brownless SM; Stockdale H; Morris AI
    Aliment Pharmacol Ther; 1990 Apr; 4(2):139-44. PubMed ID: 2151757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.
    Broocks A; Little JT; Martin A; Minichiello MD; Dubbert B; Mack C; Tune L; Murphy DL; Sunderland T
    Biol Psychiatry; 1998 Mar; 43(6):408-16. PubMed ID: 9532345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
    Broocks A; Briggs NC; Pigott TA; Hill JL; Canter SK; Tolliver TJ; Baldemore D; Murphy DL
    Psychopharmacology (Berl); 1997 Mar; 130(2):91-103. PubMed ID: 9106905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective 5-HT3 receptor antagonist, ondansetron, augments the anorectic effect of d-amphetamine in nondeprived rats.
    Cooper SJ; Greenwood SE; Gilbert DB
    Pharmacol Biochem Behav; 1993 Jul; 45(3):589-92. PubMed ID: 8332620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the 5-HT3 receptor antagonist ondansetron on gastric sensorimotor function and nutrient tolerance in healthy volunteers.
    Janssen P; Vos R; Van Oudenhove L; Tack J
    Neurogastroenterol Motil; 2011 May; 23(5):444-9, e175. PubMed ID: 21199175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers.
    Johnson BA; Campling GM; Griffiths P; Cowen PJ
    Psychopharmacology (Berl); 1993; 112(1):142-4. PubMed ID: 7871004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the 5-HT3 receptor antagonist ondansetron on amphetamine-induced hyperactivity and stereotypy in rats.
    Shankar RP; Karan RS; Handu SS; Bhargava VK
    Indian J Physiol Pharmacol; 2000 Jul; 44(3):355-8. PubMed ID: 10941627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning.
    Higgins GA; Joharchi N; Nguyen P; Sellers EM
    Psychopharmacology (Berl); 1992; 106(3):315-20. PubMed ID: 1533288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical pharmacology of ondansetron.
    Blackwell CP; Harding SM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S21-4; discussion S25-7. PubMed ID: 2533895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
    Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
    Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans.
    Dépôt M; Caillé G; Mukherjee J; Katzman MA; Cadieux A; Bradwejn J
    Neuropsychopharmacology; 1999 Feb; 20(2):177-87. PubMed ID: 9885797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal.
    Higgins GA; Nguyen P; Joharchi N; Sellers EM
    Psychopharmacology (Berl); 1991; 105(3):322-8. PubMed ID: 1839177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
    Reid K; Palmer JL; Wright RJ; Clemes SA; Troakes C; Somal HS; House F; Stott JR
    Br J Clin Pharmacol; 2000 Jul; 50(1):61-4. PubMed ID: 10886120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and preclinical antiemetic properties of ondansetron.
    Tyers MB
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.